Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer

Maria O. Nicoletto, Roberto Padrini, Eros Ferrazzi, Ottorino Nascimben, Eugenio Visonà, Salvatore Tumolo, Manlio Palumbo, Leopoldo Costa, Orazio Vinante, Silvio Monfardini, Mario V. Fiorentino

Research output: Contribution to journalArticle


36 previously treated patients (25 with anthracyclines) with advanced epithelial ovarian cancer have been treated with intraperitoneal (i.p.) mitoxantrone (M) at increasing doses. The response was evaluated through repeated laparoscopy with multiple biopsies and serial measurement of Ovarian Cancer Antigen 125 (CA 125); 11 36 patients had a complete (6 patients) or partial (5 patients) response. Toxicity (both local and general) was observed starting from 25 mg/m2 of M per cycle. The amount of drug reaching systemic circulation was monitored by measuring M plasma value after i.p. treatment. This study showed wide variations in serum levels obtained after i.p. doses ranging from 23 to 36 mg/m2. The area under the curve (AUC) of mitoxantrone plasma samples, did not correlate with the i.p. administered dose. Conversely, a correlation seems to exist between the plasma AUC and the responder status. Patients who showed clinical responses to i.p. treatment with mitoxantrone had AUCs and plasma peak levels of the drug that were significantly higher than those in non-responders (P = 0.03, Fisher's exact test).

Original languageEnglish
Pages (from-to)1242-1248
Number of pages7
JournalEuropean Journal of Cancer
Issue number9
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Nicoletto, M. O., Padrini, R., Ferrazzi, E., Nascimben, O., Visonà, E., Tumolo, S., Palumbo, M., Costa, L., Vinante, O., Monfardini, S., & Fiorentino, M. V. (1993). Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. European Journal of Cancer, 29(9), 1242-1248.